Publication | Closed Access

Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing 177Lu-PSMA-617 radioligand therapy

177Lu-psma-617 Radioligand TherapySurgical OncologyUrologyHepatologyMedicineHepatobiliary TumorLiver MetastasesLiver CancerProstatic DiseaseLiver TransplantationOncologyRadiation OncologyRadiologyHealth Sciences